MCID: CLR030
MIFTS: 55

Clear Cell Renal Cell Carcinoma

Categories: Rare diseases, Cancer diseases, Nephrological diseases

Aliases & Classifications for Clear Cell Renal Cell Carcinoma

MalaCards integrated aliases for Clear Cell Renal Cell Carcinoma:

Name: Clear Cell Renal Cell Carcinoma 49
Clear-Cell Metastatic Renal Cell Carcinoma 49 69
Conventional Renal Cell Carcinoma 69
Cystic-Multilocular Variant 49
Clear Cell Rcc 49

Classifications:



External Ids:

UMLS 69 C2931852

Summaries for Clear Cell Renal Cell Carcinoma

NIH Rare Diseases : 49 Clear cell renal cell carcinoma is a cancer of the kidney.  The name "clear cell" refers to the appearance of the cancer cells when viewed with a microscope.  Clear cell renal cell carcinoma occurs when cells in the kidney quickly increase in number, creating a lump (mass).  Though the exact cause of clear cell renal cell carcinoma is unknown, smoking, the excessive use of certain medications, and several genetic predisposition conditions (such as von Hippel Lindau syndrome) may contribute to the development of this type of cancer.  Treatment often begins with surgery to remove as much of the cancer as possible, and may be followed by radiation therapy, chemotherapy, biological therapy, or targeted therapy. Last updated: 6/1/2012

MalaCards based summary : Clear Cell Renal Cell Carcinoma, also known as clear-cell metastatic renal cell carcinoma, is related to von hippel-lindau syndrome and renal clear cell carcinoma, and has symptoms including flank pain An important gene associated with Clear Cell Renal Cell Carcinoma is VHL (Von Hippel-Lindau Tumor Suppressor), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Sunitinib and Aldesleukin have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and t cells, and related phenotypes are cellular and immune system

Related Diseases for Clear Cell Renal Cell Carcinoma

Diseases related to Clear Cell Renal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 143)
# Related Disease Score Top Affiliating Genes
1 von hippel-lindau syndrome 31.8 CCND1 HIF1A VEGFA VHL
2 renal clear cell carcinoma 31.2 CA9 HIF1A KDR OGG1 PBRM1 SETD2
3 renal cell carcinoma, nonpapillary 31.1 CA9 CD274 EGFR FLCN HIF1A KDR
4 clear cell papillary renal cell carcinoma 31.0 CA9 PBRM1 VHL
5 hypoxia 30.8 CA9 HIF1A TP53 VEGFA VHL
6 adenocarcinoma 29.1 CCND1 EGFR KDR TP53 VEGFA
7 kidney cancer 27.5 CA9 CD274 EGFR FLCN HIF1A KDR
8 multilocular clear cell renal cell carcinoma 12.3
9 multilocular cystic renal neoplasm of low malignant potential 11.5
10 chromophobe renal cell carcinoma 11.4
11 birt-hogg-dube syndrome 11.1
12 endotheliitis 10.5
13 nevus of ota 10.5 BAP1 TP53
14 fumarate hydratase deficiency 10.4 HIF1A VHL
15 acute mountain sickness 10.4 HIF1A VEGFA VHL
16 intravascular papillary endothelial hyperplasia 10.4 HIF1A VEGFA
17 retinal ischemia 10.4 HIF1A SETD2 VEGFA
18 colon adenoma 10.4 HIF1A OGG1 VEGFA
19 nodular prostate 10.4 CA9 HIF1A KDR
20 epithelioid hemangioendothelioma 10.4 KDR VEGFA VHL
21 brain ependymoma 10.4 EGFR TP53
22 retinal hemangioblastoma 10.3 CA9 HIF1A VEGFA VHL
23 familial renal papillary carcinoma 10.3 EGFR FLCN HIF1A
24 hemangioblastoma 10.3
25 limb ischemia 10.3 HIF1A KDR VEGFA
26 exudative vitreoretinopathy 1 10.3 HIF1A KDR VEGFA
27 breast carcinoma in situ 10.2 KDR TP53 VEGFA
28 angiokeratoma circumscriptum 10.2 KDR VEGFA
29 angiosarcoma 10.2 KDR TP53 VEGFA
30 soft tissue sarcoma 10.2 EGFR TP53 VEGFA
31 primary peritoneal carcinoma 10.2 EGFR TP53 VEGFA
32 renal cell carcinoma, papillary, 1 10.2
33 grade iii astrocytoma 10.2 EGFR TP53 VEGFA
34 lymphangioma 10.2 EGFR KDR VEGFA
35 angiomyolipoma 10.2
36 endometrial adenocarcinoma 10.1 EGFR TP53 VEGFA
37 cervical adenocarcinoma 10.1 EGFR RASSF1 TP53
38 pancreas adenocarcinoma 10.1 EGFR TP53 VEGFA
39 colorectal adenocarcinoma 10.1 EGFR TP53 VEGFA
40 cervical squamous cell carcinoma 10.1 EGFR RASSF1 TP53
41 body mass index quantitative trait locus 11 10.1
42 oncocytoma 10.1
43 body mass index quantitative trait locus 9 10.1
44 body mass index quantitative trait locus 8 10.1
45 body mass index quantitative trait locus 4 10.1
46 body mass index quantitative trait locus 10 10.1
47 body mass index quantitative trait locus 7 10.1
48 body mass index quantitative trait locus 12 10.1
49 body mass index quantitative trait locus 14 10.1
50 body mass index quantitative trait locus 18 10.1

Graphical network of the top 20 diseases related to Clear Cell Renal Cell Carcinoma:



Diseases related to Clear Cell Renal Cell Carcinoma

Symptoms & Phenotypes for Clear Cell Renal Cell Carcinoma

UMLS symptoms related to Clear Cell Renal Cell Carcinoma:


flank pain

MGI Mouse Phenotypes related to Clear Cell Renal Cell Carcinoma:

43 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.42 KDR FNIP1 HIF1A FLCN BAP1 CD274
2 immune system MP:0005387 10.42 FNIP1 KDR HIF1A FLCN BAP1 CD274
3 cardiovascular system MP:0005385 10.4 KDR FNIP1 HIF1A FLCN BAP1 EGFR
4 hematopoietic system MP:0005397 10.4 KDR FNIP1 HIF1A FLCN BAP1 CD274
5 homeostasis/metabolism MP:0005376 10.39 KDR FNIP1 HIF1A FLCN BAP1 CD274
6 mortality/aging MP:0010768 10.34 KDR FNIP1 HIF1A FLCN BAP1 CD274
7 embryo MP:0005380 10.25 KDR HIF1A FLCN BAP1 EGFR SETD2
8 endocrine/exocrine gland MP:0005379 10.24 HIF1A CCND1 BAP1 CA9 EGFR SCD
9 liver/biliary system MP:0005370 10.23 FNIP1 KDR HIF1A EGFR OGG1 PBRM1
10 digestive/alimentary MP:0005381 10.21 HIF1A BAP1 CA9 EGFR CCND1 RASSF1
11 integument MP:0010771 10.18 KDR HIF1A BAP1 CD274 EGFR CCND1
12 craniofacial MP:0005382 10.17 KDR HIF1A EGFR CCND1 SETD2 TP53
13 neoplasm MP:0002006 10.11 FNIP1 HIF1A FLCN BAP1 EGFR CCND1
14 muscle MP:0005369 10.01 FNIP1 KDR EGFR HIF1A BAP1 TP53
15 normal MP:0002873 9.97 KDR EGFR HIF1A CCND1 OGG1 RASSF1
16 renal/urinary system MP:0005367 9.86 FNIP1 HIF1A FLCN EGFR SCD VHL
17 respiratory system MP:0005388 9.76 KDR HIF1A CCND1 BAP1 EGFR PBRM1
18 skeleton MP:0005390 9.61 KDR EGFR HIF1A CCND1 CD274 SETD2
19 vision/eye MP:0005391 9.28 KDR HIF1A EGFR CCND1 SCD SETD2

Drugs & Therapeutics for Clear Cell Renal Cell Carcinoma

Drugs for Clear Cell Renal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
2
Aldesleukin Approved Phase 4,Phase 2,Phase 1,Early Phase 1 110942-02-4, 85898-30-2
3
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
4
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1 946414-94-4
5 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
6 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Anti-HIV Agents Phase 4,Phase 2,Phase 1,Early Phase 1
8 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
9 Interleukin-2 Phase 4,Phase 2,Phase 1,Early Phase 1
10 Anti-Retroviral Agents Phase 4,Phase 2,Phase 1,Early Phase 1
11 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Analgesics Phase 4,Phase 2,Phase 1,Early Phase 1
13 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 1,Early Phase 1
14 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1,Early Phase 1
15 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1
16 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
17 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
18
Axitinib Approved, Investigational Phase 3,Phase 2,Phase 1 319460-85-0 6450551
19
Sorafenib Approved, Investigational Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
20
Iodine Approved, Investigational Phase 3 7553-56-2 807
21
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 22916-47-8 4189
22
Everolimus Approved Phase 3,Phase 1,Phase 2 159351-69-6 6442177
23
Sirolimus Approved, Investigational Phase 3,Phase 1,Phase 2 53123-88-9 46835353 6436030 5284616
24 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
25 cadexomer iodine Phase 3
26 interferons Phase 3,Phase 2,Phase 1
27 Micronutrients Phase 3,Phase 1,Phase 2
28 Mitogens Phase 3,Phase 2,Phase 1
29 Trace Elements Phase 3,Phase 1,Phase 2
30 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
31 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
32 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
33 Immunoconjugates Phase 3,Phase 1
34 Antifungal Agents Phase 3,Phase 1,Phase 2
35 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
36 Anti-Infective Agents, Local Phase 3
37 Interferon-alpha Phase 3,Phase 2,Phase 1
38 Antibiotics, Antitubercular Phase 3,Phase 1,Phase 2
39 tyrosine Nutraceutical Phase 3,Phase 1,Phase 2
40
Heparin Approved, Investigational Phase 1, Phase 2 9005-49-6 46507594 772
41
Tinzaparin Approved Phase 1, Phase 2 9041-08-1, 9005-49-6 25244225
42
Dalteparin Approved Phase 1, Phase 2 9005-49-6
43
Ethanol Approved Phase 2 64-17-5 702
44
Mannitol Approved, Investigational Phase 2 69-65-8 6251 453
45
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
46
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
47
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
48
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
49
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
50
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941

Interventional clinical trials:

(show top 50) (show all 202)

# Name Status NCT ID Phase Drugs
1 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
2 First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma Completed NCT01521715 Phase 4 Pazopanib
3 Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy Recruiting NCT02570789 Phase 4 patients with sunitinib or pazopanib
4 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Active, not recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
5 Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
6 Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody Completed NCT00606632 Phase 3 124-Iodine-cG250 (124I-cG250)
7 Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma Completed NCT02883153 Phase 2, Phase 3 Zirconium-89 girentuximab PET/CT
8 A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy Completed NCT00738530 Phase 3 Bevacizumab [Avastin];Interferon alfa 2a [Roferon];Placebo
9 TroVax Renal Immunotherapy Survival Trial Completed NCT00397345 Phase 3
10 Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer Completed NCT00087022 Phase 3
11 Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) Completed NCT00072046 Phase 3
12 Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer Completed NCT00492258 Phase 3 sorafenib tosylate
13 Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery Recruiting NCT02535351 Phase 3 sunitinib or pazopanib
14 Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) Active, not recruiting NCT01668784 Phase 3 Everolimus
15 Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients Active, not recruiting NCT01599754 Phase 3 Axitinib;Placebo
16 Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Active, not recruiting NCT01575548 Phase 3 Pazopanib Hydrochloride
17 Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer Active, not recruiting NCT01099423 Phase 3
18 Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Active, not recruiting NCT01198158 Phase 3 Everolimus
19 S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Active, not recruiting NCT01120249 Phase 3 everolimus
20 REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT Withdrawn NCT01762592 Phase 3 Iodine (124I) Girentuximab
21 Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC) Unknown status NCT01069770 Phase 2 Sunitinib
22 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC Unknown status NCT01791387 Phase 2 Dovitinib
23 High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer Unknown status NCT01896271 Phase 2 IL-2
24 Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT) Unknown status NCT01216371 Phase 2 Sunitinib;Placebo
25 Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery Unknown status NCT00293501 Phase 1, Phase 2 tinzaparin sodium
26 Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Unknown status NCT00301990 Phase 2
27 A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy Unknown status NCT01693822 Phase 2 Axitinib
28 Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA Completed NCT02607553 Phase 2 G-202
29 BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Completed NCT01034631 Phase 1, Phase 2 Everolimus;BNC105P
30 GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma Completed NCT00244764 Phase 2 GW786034;Placebo
31 A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC). Completed NCT00796757 Phase 2 bevacizumab [Avastin];interferon alfa-2a
32 Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney Completed NCT00853021 Phase 2
33 LBH589 Treatment for Refractory Clear Cell Renal Carcinoma Completed NCT00550277 Phase 2 LBH589
34 Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma Completed NCT00729053 Phase 2 IMO-2055
35 Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer Completed NCT02002312 Phase 2 Lu-177-DOTA-girentuximab
36 Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer Completed NCT00408902 Phase 2 tandutinib
37 AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib Completed NCT00467025 Phase 2 AMG 386;Sorafenib;AMG 386 placebo IV
38 Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma Completed NCT00193258 Phase 1, Phase 2 Bevacizumab;Erlotinib;Imatinib
39 Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma Completed NCT00323739 Phase 2 bevacizumab;RAD001
40 Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus Completed NCT01715935 Phase 2 Everolimus
41 High-dose Bevacizumab in Advanced Renal Carcinoma Patients Completed NCT00455975 Phase 2 Bevacizumab
42 Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer Completed NCT00278174 Phase 2
43 Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer Completed NCT00392821 Phase 1, Phase 2 Sorafenib;RAD001
44 Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer Completed NCT01158222 Phase 2 sunitinib malate
45 Rotating Pazopanib and Everolimus to Avoid Resistance Completed NCT01408004 Phase 2 Pazopanib;Everolimus;Pazopanib;Everolimus;Everolimus;Pazopanib
46 IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease Completed NCT00523159 Phase 2 Endoxana, IMA901, Leukine;IMA901 and Leukine
47 Bryostatin 1 In Treating Patients With Progressive Kidney Cancer Completed NCT00005056 Phase 2 bryostatin 1
48 Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer Completed NCT00719264 Phase 2 RAD001(everolimus);interferon alfa-2a;bevacizumab
49 A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy Completed NCT01141569 Phase 2 Gamma-Secretase Inhibitor RO4929097
50 Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer Completed NCT01024205 Phase 2 sunitinib malate

Search NIH Clinical Center for Clear Cell Renal Cell Carcinoma

Genetic Tests for Clear Cell Renal Cell Carcinoma

Anatomical Context for Clear Cell Renal Cell Carcinoma

MalaCards organs/tissues related to Clear Cell Renal Cell Carcinoma:

38
Kidney, Endothelial, T Cells, Lung, Bone, Brain, Liver

Publications for Clear Cell Renal Cell Carcinoma

Articles related to Clear Cell Renal Cell Carcinoma:

(show top 50) (show all 940)
# Title Authors Year
1
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. ( 29378660 )
2018
2
p53I^: a new prognostic marker for patients with clear-cell renal cell carcinoma from 5.3 years of median followup. ( 29346503 )
2018
3
Pathological Bases and Clinical Impact of Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma. ( 29374850 )
2018
4
Architectural Patterns are a Relevant Morphologic Grading System for Clear Cell Renal Cell Carcinoma Prognosis Assessment: Comparisons With WHO/ISUP Grade and Integrated Staging Systems. ( 29356723 )
2018
5
The prognostic significance of nuclear expression of PHF2 and C/EBPI+ in clear cell renal cell carcinoma with consideration of adipogenic metabolic evolution. ( 29416602 )
2018
6
MiR-200c-3p inhibits cell migration and invasion of clear cell renal cell carcinoma via regulating SLC6A1. ( 29394133 )
2018
7
Downregulation of long non-coding RNA ENSG00000241684 is associated with poor prognosis in advanced clear cell renal cell carcinoma. ( 29433989 )
2018
8
Influence of Contrast Administration on Computed Tomography-Based Analysis of Visceral Adipose and Skeletal Muscle Tissue in Clear Cell Renal Cell Carcinoma. ( 29350403 )
2018
9
FOXK2 suppresses the malignant phenotype and induces apoptosis through inhibition of EGFR in clear-cell renal cell carcinoma. ( 29368368 )
2018
10
Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma. ( 29357836 )
2018
11
Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma. ( 29368125 )
2018
12
Identification of metabolism-associated genes and pathways involved in different stages of clear cell renal cell carcinoma. ( 29434939 )
2018
13
SREBP1-driven lipid desaturation supports clear cell renal cell carcinoma growth through regulation of NF-I_B signaling. ( 29183723 )
2018
14
Decreased Expression of SATB2 Associates with Tumor Growth and Predicts Worse Outcome in Patients with Clear Cell Renal Cell Carcinoma. ( 29374710 )
2018
15
Prognostic impact of concomitant loss of PBRM1 and BAP1 protein expression in early stages of clear cell renal cell carcinoma. ( 29426696 )
2018
16
Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling. ( 29396852 )
2018
17
Follistatin-like protein 1 plays a tumor suppressor role in clear-cell renal cell carcinoma. ( 29357946 )
2018
18
KLF6 Suppresses Metastasis of Clear Cell Renal Cell Carcinoma via Transcriptional Repression of E2F1. ( 27780824 )
2017
19
Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma. ( 28819235 )
2017
20
Eukaryotic Translation Initiation Factor 3b is both a Promising Prognostic Biomarker and a Potential Therapeutic Target for Patients with Clear Cell Renal Cell Carcinoma. ( 28928896 )
2017
21
Interleukin 6 induces cell proliferation of clear cell renal cell carcinoma by suppressing hepaCAM via the STAT3-dependent up-regulation of DNMT1 or DNMT3b. ( 28093267 )
2017
22
High expression of CXC chemokine receptor 6 associates with poor prognosis in patients with clear cell renal cell carcinoma. ( 28918166 )
2017
23
High mucin 5AC expression predicts adverse postoperative recurrence and survival of patients with clear-cell renal cell carcinoma. ( 28938681 )
2017
24
miR-122 Promotes Metastasis of Clear-Cell Renal Cell Carcinoma by Downregulating Dicer. ( 28921581 )
2017
25
Interference with Tim-3 protein expression attenuates the invasion of clear cell renal cell carcinoma and aggravates anoikis. ( 28112366 )
2017
26
Long non-coding RNA CCAT2 promotes cell proliferation and invasion through regulating Wnt/I^-catenin signaling pathway in clear cell renal cell carcinoma. ( 28718366 )
2017
27
Enhanced expression of caveolin-1 possesses diagnostic and prognostic value and promotes cell migration, invasion and sunitinib resistance in the clear cell renal cell carcinoma. ( 28684115 )
2017
28
An association between overexpression of DNA methyltransferase 3B4 and clear cell renal cell carcinoma. ( 28160561 )
2017
29
MicroRNA-138 attenuates epithelial-to-mesenchymal transition by targeting SOX4 in clear cell renal cell carcinoma. ( 28861152 )
2017
30
MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity. ( 27907930 )
2017
31
Prognostic Value of Tissue Based Biomarker Signature in Clear Cell Renal Cell Carcinoma. ( 28075543 )
2017
32
Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma. ( 28859644 )
2017
33
The long noncoding RNA urothelial carcinoma-associated 1 overexpression as a poor prognostic biomarker in clear cell renal cell carcinoma. ( 28459210 )
2017
34
Potential protective role of Grainyhead-like genes in the development of clear cell renal cell carcinoma. ( 28543713 )
2017
35
The Oncogenic Role of COL23A1 in Clear Cell Renal Cell Carcinoma. ( 28852123 )
2017
36
The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation. ( 29371925 )
2017
37
Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. ( 28081542 )
2017
38
Specific Localization of Missense Mutations in the VHL Gene in Clear Cell Renal Cell Carcinoma. ( 28853079 )
2017
39
Decreased TCL6 expression is associated with poor prognosis in patients with clear cell renal cell carcinoma. ( 27494890 )
2017
40
Comparison of biexponential and monoexponential DWI in evaluation of Fuhrman grading of clear cell renal cell carcinoma. ( 28050950 )
2017
41
Low CCL17 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma. ( 28178948 )
2017
42
Detection of urinary cell-free miR-210 as a potential tool of liquid biopsy for clear cell renal cell carcinoma. ( 28089386 )
2017
43
Notch 1 is a valuable therapeutic target against cell survival and proliferation in clear cell renal cell carcinoma. ( 28927098 )
2017
44
Analysis of long non-coding RNA expression profiles in clear cell renal cell carcinoma. ( 28928816 )
2017
45
A five-long non-coding RNA signature to improve prognosis prediction of clear cell renal cell carcinoma. ( 28512261 )
2017
46
Growth-induced stress enhances epithelial-mesenchymal transition induced by IL-6 in clear cell renal cell carcinoma via the Akt/GSK-3I^/I^-catenin signaling pathway. ( 28846080 )
2017
47
Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals. ( 28089832 )
2017
48
Functional variants in the low-density lipoprotein receptor gene are associated with clear cell renal cell carcinoma susceptibility. ( 29029037 )
2017
49
MCPIP1 Downregulation in Clear Cell Renal Cell Carcinoma Promotes Vascularization and Metastatic Progression. ( 28716897 )
2017
50
Sequence-Specific Detection of MicroRNAs Related to Clear Cell Renal Cell Carcinoma at fM Concentration by an Electroosmotically Driven Nanopore-Based Device. ( 28832110 )
2017

Variations for Clear Cell Renal Cell Carcinoma

Cosmic variations for Clear Cell Renal Cell Carcinoma:

9 (show top 50) (show all 1100)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM27269 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176L 19
2 COSM30474 TRIO kidney,NS,carcinoma,renal cell c.9008A>G p.N3003S 19
3 COSM26594 RNF144A kidney,NS,carcinoma,renal cell c.410C>T p.A137V 19
4 COSM26987 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 19
5 COSM26614 RABGAP1 kidney,NS,carcinoma,renal cell c.1533T>A p.H511Q 19
6 COSM30530 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 19
7 COSM27618 KMT2A kidney,NS,carcinoma,renal cell c.5711C>T p.A1904V 19
8 COSM30502 ITPR3 kidney,NS,carcinoma,renal cell c.4574G>T p.C1525F 19
9 COSM28415 DOCK1 kidney,NS,carcinoma,renal cell c.1306G>T p.D436Y 19
10 COSM30531 COPS4 kidney,NS,carcinoma,renal cell c.385G>C p.G129R 19
11 COSM25654 CDC5L kidney,NS,carcinoma,renal cell c.1196G>A p.R399Q 19
12 COSM30471 ARHGAP20 kidney,NS,carcinoma,renal cell c.1355A>G p.D452G 19
13 COSM249350 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.2363A>C p.Q788P 13
14 COSM249389 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.121G>C p.E41Q 13
15 COSM249348 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 13
16 COSM249454 ZNF521 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3298A>G p.S1100G 13
17 COSM30510 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3559G>A p.V1187I 13
18 COSM249421 WWP2 kidney,NS,carcinoma,clear cell renal cell carcinoma c.2056G>C p.E686Q 13
19 COSM6201648 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1228+1G>C p.? 13
20 COSM1272065 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.332C>A p.P111H 13
21 COSM20759 WNK3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3809C>A p.T1270N 13
22 COSM30715 WISP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.868T>C p.C290R 13
23 COSM249519 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3300A>T p.E1100D 13
24 COSM249385 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1286A>G p.Q429R 13
25 COSM26611 VPS13B kidney,NS,carcinoma,clear cell renal cell carcinoma c.2580C>T p.Y860Y 13
26 COSM18132 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.463+2T>C p.? 13
27 COSM30221 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.326T>A p.I109N 13
28 COSM17721 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.241C>T p.P81S 13
29 COSM14400 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.194C>T p.S65L 13
30 COSM17789 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.525C>A p.Y175* 13
31 COSM14376 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.464-1G>A p.? 13
32 COSM14309 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.478G>A p.E160K 13
33 COSM14408 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.485G>A p.C162Y 13
34 COSM17612 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.481C>T p.R161* 13
35 COSM1169455 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.525C>G p.Y175* 13
36 COSM17928 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.463G>C p.V155L 13
37 COSM17948 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.172C>A p.R58R 13
38 COSM25678 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.563T>C p.L188P 13
39 COSM18379 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.505C>T p.L169L 13
40 COSM3734681 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.511A>T p.K171* 13
41 COSM17658 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.286C>T p.Q96* 13
42 COSM17934 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.452T>C p.I151T 13
43 COSM14363 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.458T>C p.L153P 13
44 COSM17651 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.445G>C p.A149P 13
45 COSM34019 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.361G>T p.D121Y 13
46 COSM14372 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.203C>A p.S68* 13
47 COSM144717 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.287A>C p.Q96P 13
48 COSM14407 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.388G>C p.V130L 13
49 COSM17839 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.317G>C p.G106A 13
50 COSM3727795 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.385C>A p.L129M 13

Copy number variations for Clear Cell Renal Cell Carcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 135083 2 111395408 111435684 Copy number BUB1 Clear cell renal cell carcinoma
2 181389 4 120800000 123800000 Copy number MAD2L1 Clear cell renal cell carcinoma

Expression for Clear Cell Renal Cell Carcinoma

Search GEO for disease gene expression data for Clear Cell Renal Cell Carcinoma.

Pathways for Clear Cell Renal Cell Carcinoma

Pathways related to Clear Cell Renal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.99 CCND1 EGFR KDR RASSF1 TP53 VEGFA
2 12.67 CCND1 EGFR HIF1A RASSF1 TP53 VEGFA
3
Show member pathways
12.43 EGFR FLCN FNIP1 KDR TP53
4
Show member pathways
12.36 CCND1 PFKP SCD TP53
5 12.32 CCND1 EGFR MIR21 RASSF1 TP53 VEGFA
6 12.13 CCND1 EGFR TP53 VEGFA
7 12.09 CCND1 EGFR TP53 VEGFA
8
Show member pathways
12.08 CCND1 EGFR TP53 VEGFA
9
Show member pathways
11.95 CCND1 EGFR FLCN HIF1A TP53 VEGFA
10 11.91 CCND1 HIF1A PFKP TP53
11 11.89 CCND1 HIF1A TP53 VEGFA
12 11.83 EGFR HIF1A VEGFA VHL
13 11.76 CA9 HIF1A KDR
14
Show member pathways
11.76 HIF1A KDR VEGFA VHL
15
Show member pathways
11.62 CCND1 EGFR HIF1A VEGFA
16 11.61 CA9 HIF1A VEGFA
17 11.55 EGFR HIF1A PFKP TP53
18 11.5 CCND1 EGFR TP53
19 11.47 CCND1 EGFR HIF1A KDR MIR21 TP53
20 11.42 CCND1 EGFR RASSF1 TP53 VEGFA
21
Show member pathways
11.39 EGFR KDR VEGFA
22 11.38 EGFR KDR VEGFA
23 11.36 HIF1A TP53 VEGFA VHL
24 11.32 HIF1A TP53 VEGFA
25 11.27 KDR VEGFA VHL
26 11.27 CCND1 HIF1A TP53 VEGFA
27 11.07 HIF1A KDR VEGFA
28 10.81 HIF1A TP53 VHL
29 10.72 HIF1A TP53
30 10.58 HIF1A VEGFA

GO Terms for Clear Cell Renal Cell Carcinoma

Cellular components related to Clear Cell Renal Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.47 BAP1 CA9 CCND1 EGFR FLCN HIF1A

Biological processes related to Clear Cell Renal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.89 HIF1A KDR SETD2 VEGFA
2 negative regulation of cell proliferation GO:0008285 9.85 BAP1 MIR21 PBRM1 RNF139 TP53 VHL
3 positive regulation of angiogenesis GO:0045766 9.8 HIF1A KDR MIR21 VEGFA
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.77 EGFR FNIP1 VEGFA
5 positive regulation of endothelial cell proliferation GO:0001938 9.74 HIF1A KDR VEGFA
6 vasculogenesis GO:0001570 9.73 KDR SETD2 VEGFA
7 positive regulation of endothelial cell migration GO:0010595 9.72 KDR MIR21 VEGFA
8 positive regulation of cell migration GO:0030335 9.72 CD274 EGFR KDR MIR21 VEGFA
9 lactation GO:0007595 9.7 CCND1 HIF1A VEGFA
10 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.65 HIF1A VEGFA
11 positive regulation of blood vessel endothelial cell migration GO:0043536 9.65 HIF1A KDR VEGFA
12 response to inorganic substance GO:0010035 9.64 BAP1 TP53
13 digestive tract morphogenesis GO:0048546 9.64 EGFR HIF1A
14 cell migration involved in sprouting angiogenesis GO:0002042 9.63 KDR VEGFA
15 positive regulation of leukocyte migration GO:0002687 9.63 TP53 VEGFA
16 negative regulation of gene expression GO:0010629 9.63 FLCN HIF1A KDR MIR21 VEGFA VHL
17 TOR signaling GO:0031929 9.62 FLCN FNIP1
18 positive regulation of positive chemotaxis GO:0050927 9.61 KDR VEGFA
19 collagen metabolic process GO:0032963 9.61 HIF1A MIR21
20 mitotic G1 DNA damage checkpoint GO:0031571 9.58 CCND1 TP53
21 negative regulation of TOR signaling GO:0032007 9.58 FLCN FNIP1 HIF1A
22 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.56 CA9 HIF1A VEGFA VHL
23 negative regulation of apoptotic process GO:0043066 9.56 EGFR HIF1A KDR MIR21 OGG1 TP53
24 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.54 KDR VEGFA
25 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.51 HIF1A VEGFA
26 response to UV-A GO:0070141 9.46 CCND1 EGFR
27 regulation of pro-B cell differentiation GO:2000973 9.43 FLCN FNIP1
28 positive regulation of protein phosphorylation GO:0001934 9.17 CCND1 EGFR FLCN FNIP1 KDR MIR21
29 negative regulation of transcription by RNA polymerase II GO:0000122 10.05 CCND1 FLCN FNIP1 TP53 VEGFA VHL
30 positive regulation of cell proliferation GO:0008284 10.02 CCND1 EGFR KDR MIR21 VEGFA

Molecular functions related to Clear Cell Renal Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.02 CCND1 EGFR HIF1A TP53 VHL
2 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 8.96 EGFR KDR
3 protein binding GO:0005515 10.09 BAP1 CA9 CCND1 CD274 EGFR FLCN

Sources for Clear Cell Renal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....